Showing 21,121 - 21,140 results of 30,146 for search '(( significant decrease decrease ) OR ( significant ((linear decrease) OR (year increase)) ))', query time: 0.46s Refine Results
  1. 21121

    Table 1_Nonlinear association of a composite metabolic index (ZJU index) with hypertension: a cross-sectional study of NHANES 2003–2018.docx by Haibo Gong (1648705)

    Published 2025
    “…Participants with higher ZJU index values had significantly increased risk compared to the reference group (OR = 3.73; 95% CI: 3.25–4.29). …”
  2. 21122

    Data associated with manuscript 'Enhanced encephalitic tropism of bovine H5N1 compared to the Vietnam H5N1 isolate in mice' by Neeltje van Doremalen (8816015)

    Published 2025
    “…<p dir="ltr">In recent years, the landscape of highly pathogenic avian influenza (HPAI) virus infections has shifted, as evidenced by an increase in infections among mammals. …”
  3. 21123

    Supplementary Material for: Clopidogrel Use in Saudi Arabia: Prescription Patterns and Prevalence of Common Concurrent Medications by figshare admin karger (2628495)

    Published 2025
    “…This study found that 32.05% of patients co-used statins, 28.61% used PPIs, and 22.22% used antiplatelets, highlighting significant risks of DDIs. These interactions may compromise efficacy or increase adverse outcomes, such as bleeding. …”
  4. 21124

    Data Sheet 1_Analysis of the level of polypharmacy in patients from an isolated rural area: effect of age, sex, and chronic diseases.pdf by Susana Abdala Kuri (21515237)

    Published 2025
    “…Introduction<p>The increase in life expectancy and the greater number of chronic diseases have led to a greater use of medications. …”
  5. 21125

    Effect of induced astigmatism on vestibulo-ocular reflex by Javad Heravian Shandiz (20562819)

    Published 2025
    “…</p> <p>The latencies of N1 and P1 significantly increased with the increasing power of induced astigmatism; however, the powers of astigmatism had no effect on the amplitude of N1-P1. …”
  6. 21126

    Table 1_Methodological panorama of clinical trials for diabetic foot ulcers: a scope review of design, implementation and reporting.xlsx by Shuo Zhang (30844)

    Published 2025
    “…</p>Result<p>The study revealed a rapid increase in the number of clinical trials focusing on DFU in recent years. …”
  7. 21127

    Table 1_Unveiling the role of stress hyperglycemia in predicting mortality for critically ill hemorrhagic stroke patients: insights from MIMIC-IV.docx by Yong Yue (569569)

    Published 2025
    “…Multivariate Cox regression analysis indicated that elevated SHR was independently associated with increased ACM at 30 days (adjusted hazard ratio [aHR]: 1.41; 95% confidence interval [CI]: 1.10–1.81; P = 0.006), 90 days (aHR: 1.33; 95% CI: 1.08–1.65; P = 0.008), and 1 year (aHR: 1.27; 95% CI: 1.05–1.54; P = 0.014). …”
  8. 21128

    Data Sheet 2_Unveiling the role of stress hyperglycemia in predicting mortality for critically ill hemorrhagic stroke patients: insights from MIMIC-IV.pdf by Yong Yue (569569)

    Published 2025
    “…Multivariate Cox regression analysis indicated that elevated SHR was independently associated with increased ACM at 30 days (adjusted hazard ratio [aHR]: 1.41; 95% confidence interval [CI]: 1.10–1.81; P = 0.006), 90 days (aHR: 1.33; 95% CI: 1.08–1.65; P = 0.008), and 1 year (aHR: 1.27; 95% CI: 1.05–1.54; P = 0.014). …”
  9. 21129

    Data Sheet 1_Unveiling the role of stress hyperglycemia in predicting mortality for critically ill hemorrhagic stroke patients: insights from MIMIC-IV.pdf by Yong Yue (569569)

    Published 2025
    “…Multivariate Cox regression analysis indicated that elevated SHR was independently associated with increased ACM at 30 days (adjusted hazard ratio [aHR]: 1.41; 95% confidence interval [CI]: 1.10–1.81; P = 0.006), 90 days (aHR: 1.33; 95% CI: 1.08–1.65; P = 0.008), and 1 year (aHR: 1.27; 95% CI: 1.05–1.54; P = 0.014). …”
  10. 21130

    Data Sheet 3_Unveiling the role of stress hyperglycemia in predicting mortality for critically ill hemorrhagic stroke patients: insights from MIMIC-IV.pdf by Yong Yue (569569)

    Published 2025
    “…Multivariate Cox regression analysis indicated that elevated SHR was independently associated with increased ACM at 30 days (adjusted hazard ratio [aHR]: 1.41; 95% confidence interval [CI]: 1.10–1.81; P = 0.006), 90 days (aHR: 1.33; 95% CI: 1.08–1.65; P = 0.008), and 1 year (aHR: 1.27; 95% CI: 1.05–1.54; P = 0.014). …”
  11. 21131

    Data Sheet 5_Unveiling the role of stress hyperglycemia in predicting mortality for critically ill hemorrhagic stroke patients: insights from MIMIC-IV.pdf by Yong Yue (569569)

    Published 2025
    “…Multivariate Cox regression analysis indicated that elevated SHR was independently associated with increased ACM at 30 days (adjusted hazard ratio [aHR]: 1.41; 95% confidence interval [CI]: 1.10–1.81; P = 0.006), 90 days (aHR: 1.33; 95% CI: 1.08–1.65; P = 0.008), and 1 year (aHR: 1.27; 95% CI: 1.05–1.54; P = 0.014). …”
  12. 21132

    Data Sheet 6_Unveiling the role of stress hyperglycemia in predicting mortality for critically ill hemorrhagic stroke patients: insights from MIMIC-IV.pdf by Yong Yue (569569)

    Published 2025
    “…Multivariate Cox regression analysis indicated that elevated SHR was independently associated with increased ACM at 30 days (adjusted hazard ratio [aHR]: 1.41; 95% confidence interval [CI]: 1.10–1.81; P = 0.006), 90 days (aHR: 1.33; 95% CI: 1.08–1.65; P = 0.008), and 1 year (aHR: 1.27; 95% CI: 1.05–1.54; P = 0.014). …”
  13. 21133

    Data Sheet 4_Unveiling the role of stress hyperglycemia in predicting mortality for critically ill hemorrhagic stroke patients: insights from MIMIC-IV.pdf by Yong Yue (569569)

    Published 2025
    “…Multivariate Cox regression analysis indicated that elevated SHR was independently associated with increased ACM at 30 days (adjusted hazard ratio [aHR]: 1.41; 95% confidence interval [CI]: 1.10–1.81; P = 0.006), 90 days (aHR: 1.33; 95% CI: 1.08–1.65; P = 0.008), and 1 year (aHR: 1.27; 95% CI: 1.05–1.54; P = 0.014). …”
  14. 21134

    DataSheet1_Impact of intraspecific genetic variation on interspecific competition: a theoretical case study of forage binary mixtures.docx by Béatrice Wolff (19758981)

    Published 2024
    “…Introduction<p>Increasing intraspecific genetic variation (IV) has been identified as a potential factor to improve productivity and stabilise botanical composition in plant communities. …”
  15. 21135

    DataSheet1_Impact of intraspecific genetic variation on interspecific competition: a theoretical case study of forage binary mixtures.docx by Béatrice Wolff (19758981)

    Published 2024
    “…Introduction<p>Increasing intraspecific genetic variation (IV) has been identified as a potential factor to improve productivity and stabilise botanical composition in plant communities. …”
  16. 21136

    Table 1_Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer.xlsx by Jing Nie (139250)

    Published 2025
    “…</p>Methods<p>Using a Markov model over 5-year boundary and data from the ETER701 trials, we analyzed quality-adjusted life-years (QALYs), incremental cost-effectiveness ratio (ICER), total cost, incremental net health benefit (INHB) and incremental monetary benefit (INMB). …”
  17. 21137

    Supplementary Material for: IgA Nephropathy and the Risk of Primary Infections: A Swedish population-based cohort study by figshare admin karger (2628495)

    Published 2025
    “…The increased risk of sepsis warrants clinical awareness and prevention.…”
  18. 21138

    Data Sheet 1_Crop-specific response of soil prokaryotic community to long-term intensification management: the importance of crop phase at sampling.pdf by Juan P. Frene (12227753)

    Published 2024
    “…Nitrogen fertilization had a minor effect (3.12%) and was detected only after maize sampling; cover crops had no significant effect. However, the presence of cover crops showed higher alpha diversity and an increased abundance of Proteobacteria. …”
  19. 21139

    Table 2_Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer.xlsx by Jing Nie (139250)

    Published 2025
    “…</p>Methods<p>Using a Markov model over 5-year boundary and data from the ETER701 trials, we analyzed quality-adjusted life-years (QALYs), incremental cost-effectiveness ratio (ICER), total cost, incremental net health benefit (INHB) and incremental monetary benefit (INMB). …”
  20. 21140

    Table 3_Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer.xlsx by Jing Nie (139250)

    Published 2025
    “…</p>Methods<p>Using a Markov model over 5-year boundary and data from the ETER701 trials, we analyzed quality-adjusted life-years (QALYs), incremental cost-effectiveness ratio (ICER), total cost, incremental net health benefit (INHB) and incremental monetary benefit (INMB). …”